Table 1 Comparison of baseline characteristics and infectious complications between patients who received fosfomycin and those who received flumarin for antimicrobial prophylaxis for TRUS guided prostate biopsy
| Â | Fosfomycin | Flumarin | p |
|---|---|---|---|
n | 333 | 2567 | Â |
Age | 68.3 ± 8.8 | 67.5 ± 8.7 | 0.1611 |
DM | 54 (16.2%) | 405 (15.8%) | 0.8362 |
Health care risk* | 8 (2.4%) | 120 (4.7%) | 0.0582 |
Operation < 6 months | 6 (1.8%) | 47 (1.8%) | 0.9702 |
UTI < 6 months | 4 (1.2%) | 18 (0.7%) | 0.3083 |
Prior prostate biopsy | 17 (5.1%) | 344 (13.4%) | 0.0002 |
Prior antibiotics < 6 months | 57 (17.1%) | 503 (29.6%) | 0.2652 |
PSA Group | Â | Â | 0.2612 |
 < 10 | 196 (58.9%) | 1566 (61.0%) |  |
 10–20 | 66 (19.8%) | 547 (21.3%) |  |
 > 20 | 71 (21.3%) | 454 (17.7%) |  |
Prostate size | 44.5 ± 20.9 | 44.9 ± 20.8 | 0.7891 |
No of biopsy cores | 11.4 ± 1.8 | 10.8 ± 2.0 | 0.0001 |
Cancer detection | 146 (43.8%) | 887 (34.6%) | 0.0012 |
Infectious complications (overall) | 19 (5.7%) | 220 (8.6%) | 0.0742 |
Infectious complications (hospitalization) | 3 (0.9%) | 8 (0.3%) | 0.0732 |